Abstract. Personalized chemotherapy with the use of biomarkers helps to maximize clinical efficiency. Therefore, the present study aimed to identify a potential method for identifying biomarkers in esophageal cancer. A total of 49 freshly resected tumor tissues and 72 paraffin-embedded specimens from patients with esophageal cancer were obtained. mRNA expression levels of ERCC1, BRCA1, TUBB3, FBW7, RRM1, MDM2, TS and TOP1 were measured quantitative reverse transcription polymerase chain reaction (RT-qPCR). In vitro chemosensitivity to cisplatin, docetaxel, gemcitabine, etoposide, fluorouracil and irinotecan were tested using histoculture drug response assay (HDRA). BRCA1 mRNA levels were positively correlated with resistance to cisplatin (P= 0.027) and sensitivity to docetaxel (P=0.002). TS mRNA levels were inversely correlated with fluorouracil sensitivity (P= 0.044), and TOP1 mRNA expression was positively correlated with irinotecan sensitivity (P= 0.008). In addition, high BRCA1 mRNA levels correlated with decreased median overall survival (mOS; P<0.001) and response rate (RR; P= 0.002) in cisplatin-fluorouracil chemotherapy group and also correlated with increased mOS (P<0.001) and RR (P= 0.023) in docetaxel-fluorouracil chemotherapy group. Overall, these results suggested that HDRA combined with RT-qPCR may serve as an effective method for screening biomarkers in personalized chemotherapy for esophageal cancer.
Introduction
Esophageal cancer is one of the leading causes of cancer-associated mortalities in China (1, 2) . Chemotherapy has been considered an essential method to treat esophageal cancer. However, the efficacy of the chemotherapeutic agents has been limited with rates between 11 and 35% (3) (4) (5) . Furthermore, to date, there is no 'gold standard' chemotherapy for esophageal cancer. With the development of pharmacogenomics and pharmacogenetics, tumor heterogeneity is considered to be a significant factor that is responsible for the failure of conventional chemotherapeutics (6, 7) . In predictive biomarker studies, a number of genes have been reported to predict response to chemotherapy for solid tumors, including excision repair cross-complementation group 1 (ERCC1), breast cancer type 1 gene (BRCA1) or ADP ribosylation factor like GTPase 6 interacting protein 5 (JWA) for cisplatin (8) , BRCA1, tubulin β-3 class III (TUBB3) or F-box and WD repeat domain containing 7 (FBW7) for docetaxel (9) (10) (11) , thymidylate synthetase (TS) for fluorouracil (12) , and ribonucleotide reductase catalytic subunit M1 (RRM1) for gemcitabine (13) , murine double minute 2 (MDM2) for etoposide (14) and DNA topoisomerase 1 (TOP1) for irinotecan (15) . Additionally, a few of the genes, including BRCA1, JWA and TS, have been validated for their clinical value in esophageal cancer (8, 12) . However, the clinical value of the aforementioned biomarkers for chemotherapeutic agents such as irinotecan (16) , gemcitabine (5) and etoposide (17) , which are not commonly used but exhibit moderate activity for treating esophageal cancer, remains unclear. Therefore, it is important to investigate practical methods, which can be used to screen and identify appropriate biomarkers for personalized therapy of esophageal cancer with chemotherapeutic agents of which there are limited clinical application data available.
The histoculture drug response assay (HDRA) is one of a number of in vitro tests for chemosensitivity, which allows the characteristics of the three-dimensional tissue structure to be maintained (18) . HDRA has the advantage of being able Combination of histoculture drug response assay and qPCR as an effective method to screen biomarkers for personalized chemotherapy in esophageal cancer BIN WEI 1* , JIRU WANG to maintain three-dimensional tissue structure and may be able to more accurately mimic the in vivo response compared with a cell culture model (18, 19) . The clinical reliability and utility of HDRA have been examined in several clinical studies for various solid tumors, including oral squamous cell carcinoma, head and neck, gastric, colorectal and ovarian cancer (20) (21) (22) . Furthermore, HDRA has gradually been applied to identify candidate genes or gene sets with the capacity to predict efficiency of chemotherapeutic and targeted agents. Therefore, in the present study, HDRA was employed to evaluate the sensitivity of chemotherapeutic agents (cisplatin, docetaxel, gemcitabine, etoposide, fluorouracil and irinotecan) in tumor tissues, and the quantitative reverse transcription polymerase chain reaction method was performed to detect the mRNA expression of ERCC1, BRCA1, TUBB3, FBW7, RRM1, MDM2, TS and TOP1. Additionally, the present study verified the predictive value of a potential biomarker in patients with advanced esophageal cancer.
Patients and methods
Patients and sample collection. All patients and relevant clinical data were obtained from the Huai'an First People's Hospital, Nanjing Medical University (Huai'an, China) from May 2012 to June 2013. The median age was 62, and the majority of patients were male. Written informed consent for the use of tissue specimens was obtained from all patients, and the protocols for the present study were approved by the Ethics Committee of Huai'an First People's Hospital, Nanjing Medical University. The surgically resected tumor specimens were obtained from 49 patients. Each specimen was divided into three parts. One part of the specimens was kept in 4˚C Hanks' balanced salt solution with 1% penicillin/streptomycin, and HDRA was employed to measure inhibition rates of chemotherapeutic agents in vitro within 15 min. Another part of the specimen was fixed by 10% formalin for 24 h at room temperature and embedded with paraffin for pathological observation. The rest of the tissue was stored in -80˚C for further detection of gene expression.
The paraffin-embedded tumor materials were collected from 72 cases with advanced esophageal cancer that received cisplatin-fluorouracil (cisplatin 25 mg/m 2 on day 1-3; fluorouracil 500 mg/m 2 on day 1-5) or docetaxel-fluorouracil (docetaxel 60-75 mg/m 2 ; fluorouracil 500 mg/m 2 on day 1-5) chemotherapy. Chemotherapy was repeated every 3-4 weeks for a maximum of six cycles unless patients had disease progression or in unsupportable adverse reactions.
HDRA. HDRA procedures were performed as previously described by Furukawa et al (18) . Cancerous portions of specimens were washed three times with Hank's balanced salt solution and divided into ~10 mg pieces. Then, the tissue fragments were placed on prepared collagen sponge surfaces (Health Design, Rochester, NY, USA) in 24-well plates and incubated for 6 days in RPMI 1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 20% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) at 37˚C in 5% CO 2 . The concentration of each agent was determined by a preliminary experiment with 25% growth inhibition (IC 25 value) as follows: 100 µg/ml for cisplatin, 30 µg/ml for docetaxel (Jiangsu Hengrui Medicine Co., Ltd., Nanjing, China), 10 µg/ml for fluorouracil, 30 µg/ml for gemcitabine, 10 µg/ml for etoposide and 10 µg/ml for irinotecan (Jiangsu Haosen Medicine Company, Nanjing, China).
Following histoculture, 100 µl Hank's balanced salt solution containing 0.1 mg/ml type I collagenase (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and 100 µl MTT solution (2 mg/ml) were added to each well. The plates were incubated at 37˚C for another 24 h. Following extraction with dimethyl sulfoxide, the absorbance of the solution in each well was measured with microplate reader at 540 nm. Absorbance per gram of cultured tumor tissue was calculated from the mean absorbance from 8 parallel culture wells, and the weight of tumor tissue was determined prior to culture. The inhibition rate (IR) was calculated using the following formula: IR=(1-T/C) x100%, where T is the mean absorbance of the treated tumor/weight, and C is the mean absorbance of the control tumor/weight.
Quantitative reverse transcription polymerase chain reaction (RT-qPCR).
Frozen tissues (~10 mg/per sample) were grinded in liquid nitrogen, and the total RNA was extracted by using the TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). For paraffin-embedded tumor specimens, micro-dissection was performed to ensure serial sections of 7 mm in thickness with >80% of tumor cells. The pellet of micro-dissected cells was resuspended in Trizol reagent supplemented with proteinase K to extract RNA. Then RNA was reverse-transcribed with FastQuant RT kit (Tiangen Biotech Co., Ltd., Beijing, China). Each sample was detected in triplicate with RNase-free water, and commercial RNA as negative and positive control. Template cDNA was amplified with specific primers for different genes with the SuperReal PreMix Plus (Tiangen Biotech Co., Ltd., Beijing, China) by using the Real-Time PCR Detection system (Roche Applied Science Madison, WI, USA). The sequences of the primers are provided in Table I . Relative gene expression quantification was calculated using the Cq method. Final values were determined by the formula 2 -ΔΔCq and were analyzed with the Stratagene analysis software (version Mx3000P; Agilent Technologies, Inc., Santa Clara, CA, USA).
Statistical analysis. The Mann-Whitney U and Kruskal-Wallis tests were used to analyze the association between inhibition rates of agents or gene expression levels and clinical characteristics. The mean value was employed as the cutoff point of gene levels to divide the patients into low or high expression groups. The Mann-Whitney U test was used to compare the inhibition rates between the two groups. Clinical response was evaluated according to the Response Evaluation Criteria in Solid Tumors (23) . Overall survival (OS) was calculated from the date of diagnosis to the date of last follow-up or mortality from any cause. The distributions of OS were analyzed using Kaplan-Meier method and compared with the two-sided log-rank test. P<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed by SPSS 19.0 software (IBM Corp., Armonk, NY, USA).
Results
Patient characteristics. Characteristics of all patients are shown in Table II . In the HDRA cohort, all patients were in stages II-III (24) at the time of diagnosis. In the clinical cohort, the patients were restricted to stages III-IV. In the clinical cohort, 34 patients treated with cisplatin-fluorouracil-based chemotherapy with response rate (RR) of 38.2% Table I . Primer sequences used for gene analysis.
Genes
Forward primer (5'-3') Reverse primer (5'-3')   ERCC1  ACCCCTCGACGAGGATGA  GATGGC ATATTCGGCGTAGGT  BRCA1  TCCCATCTGTCTGGAGTTGA  GCCCTTTCTTCTGGTTGAGA  TUBB3  GCAGTCGCAGTTTTCACACTC  GCAGTCGCAGTTTTCACACTC  FBXW7  GGCCAAAATGATTCCCAGCAA  ACTGGAGTTCGTGACACTGTTA  RRM1  AGCAGCCAAAGTATCTAGTTCCA  AGCAGCCAAAGTATCTAGTTCCA  MDM2  TCGTCGGGTGAGGGTACTG  AACCACTTCTTGGAACCAGGT  TS  CTTCAGCGAGAACCCAGACC  TCCAGCCCAACCCCTAAAGAC  TOP1 GAGAGCTGTAGCCCTGTACTTCATC CAGTGTCCGCTGTTTCTCCTT Table II . Clinical characteristics of patients with esophageal cancer. Genes mRNA expression levels (mean ± standard error) Table III . Association between inhibition rates of chemotherapy agents and clinical characteristics. Inhibition rates of chemotherapeutic agents. The ability of 6 chemotherapeutic agents to inhibit the growth of 49 tumor specimens was successfully tested using HDRA. Not only did the spectrum of sensitive agent vary between individual patients, but the inhibition rate of each agent also varied and ranged widely. The average inhibition rates were as follows: Cisplatin, 37.6% (95% CI, 35. (Fig. 1A) . However, there was no significant association between inhibition rates and clinical characteristics (all P>0.05, Table III) .
Inhibition rates (%) of chemotherapy agents (mean and 95% CI) a --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Gene expression levels. The mRNA expression levels of 8 genes were detected in all tumor tissues, with mean levels of 4.7 (95% CI, 3.7-5.7) for ERCC1; 1.2 (95% CI, 0.9-1.5) for BRCA1; 1.1 (95% CI, 0.7-1.5) for TUBB3; 6.5 (95% CI, 3.5-9.5) for FBW7; 1.8 (95% CI, 1.3-2.2) for RRM1; 6.1 (95% CI, 4.5-7.6) for MDM2; 1.5 (95% CI, 1.0-2.1) for TS; and 3.6 (95% CI, 2.4-4.9) for TOP1 (Fig. 1B) . No association between clinical characteristics and gene expression was identified (all P>0.05, Table IV) .
Association between gene expression and chemosensitivity.
The inhibition rates of various chemotherapeutic agents are indicated in Fig. 2 . The inhibition rate of cisplatin in the group with low BRCA1 mRNA expression was higher compared with the group with high expression (44.7 vs. 32.7%; P=0.027; low expression vs. high expression group; Fig. 2B ), while the result of docetaxel inhibition rate was the opposite with a higher inhibition rate in the high expression group (14.8 vs. 26.4%, low expression vs. high expression group; P=0.002; Fig. 2C ). The tissues with low TS mRNA expression levels had a higher sensitivity to fluorouracil compared with those with high expression levels (21.9 vs. 14.1%; P=0.044; Fig. 2H ). The group with high TOP1 mRNA expression levels was more sensitive to irinotecan compared with those with low expression levels (18.0 vs. 28.4%; P= 0.031; Fig. 2I ). However, statistically insignificant associations between genes levels and inhibition rates were also observed as follows: ERCC1 with cisplatin (38.2 vs. 48.0%, P= 0.120; Fig. 2A Association between BRCA1 expression and clinical outcomes in patients treated with chemotherapy. In order to verify whether the predictive effects of screened biomarkers in personalized chemotherapy is consistent with in vitro chemosensitivity, the authors of the present study further investigated the associations of BRCA1 mRNA expression with clinical outcomes in patients with advanced esophageal cancer, who were treated with cisplatin-fluorouracil or docetaxel-fluorouracil chemotherapy. The findings indicated that patients treated with cisplatin-fluorouracil chemotherapy with low BRCA1 expression had increased mOS (16.5 vs. 6.5 months; P<0.001; Fig. 3A , (57.1 vs. 20.8%; P=0.023; Table V ) compared with those with low BRCA1 expression.
Discussion
Treatment options in esophageal cancer have advanced over the last several years with the introduction of effective chemotherapeutics. However, personalized therapy is far from being implemented due to the lack of effective predictive biomarkers (25) . Currently, the prediction of response to chemotherapy at the molecular level is primarily based on data derived from in vitro experiments (26) (27) (28) . Furthermore, studies, which utilize cell culture model of tumors, organoid cultures or xenografts currently best mimic the characteristics of an in vivo tumor (29) . An in vitro histoculture system is able to maintain the structure of the three-dimensional tissue and the natural tumor environment (18, 19) . Despite mouse xenograft models having the advantages of being able to mimic the micro-environmental conditions, tumor architecture, angiogenesis and metastasis present in a real patient, the in vitro histoculture system has relative advantages of good availability, low cost, ease of handling and short intervention time. Therefore, in the present study the HDRA histoculture system was selected to determine chemosensitivity. In addition, 8 parallel culture wells were designed to test the chemosensitivity of different parts of tumor specimen to avoid the issue of tumor heterogeneity. The efficacy rate for an individual agent using HDRA in vitro has a considerable good correlation with clinical response rate to each agent (30, 31) . Previous studies have reported that TS and DPD expression are correlated with fluorouracil sensitivity (32) (33) (34) (35) . It was also reported that ERCC1 expression and SULF2 methylation are correlated with platinum sensitivity (33, 36) . Furthermore, CXCR4 and TUBB3 expression are correlated with docetaxel sensitivity (37, 38) . Aprataxin (APTX) expression also has been correlated with irinotecan sensitivity (29, 33) , and MET expression has been correlated with crizotinib sensitivity (39) using HDRA. These results suggest that HDRA can be used in predictive biomarker studies. In addition, the qPCR method, which may be more clinically useful with the benefits of being able to provide more quantitative and accurate measurement compared with fluorescence in situ hybridization and immunohistochemistry, has been widely employed to detect the expression levels of candidate genes in the aforementioned studies. Therefore, in the present study, a total of 8 candidate biomarkers were selected based on literature review, and the gene expression patterns were analyzed using qPCR. A number of potential biomarkers for chemotherapy in esophageal cancer were identified, including BRCA1 for docetaxel or cisplatin, TS for fluorouracil and TOP1 for irinotecan. The authors then considered whether combining HDRA with qPCR for biomarker discovery may provide novel opportunities for prediction of individual response to chemotherapy. Despite the identification of a number of candidate biomarkers for esophageal cancer in the present study, whether the predictive functions of these genes may be reproduced in clinical practice still requires validation.
Previous studies have evaluated the predictive value of potential biomarkers generated from HDRA in xenograft model and in clinical settings. Shen et al (29) established different mice models with patient-derived gastric cancer xenografts and demonstrated that tumor growth is significantly suppressed in the cohort with sensitive-signature based on the expression of APTX, BRCA1 and TOP1. Yang et al (39) have reported that patient-derived tumor xenograft models with higher MET expression exhibited high sensitivity to crizotinib, and tumor shrinkage was observed in a patient with advanced gastric cancer and MET overexpression following crizotinib treatment. However, differences in metabolism, body size and genetic background between the host species and humans may have an impact on the predictive value of biomarkers.
Therefore, in the present study, a total of 72 patients with advanced esophageal cancer, who were treated with cisplatin-fluorouracil or docetaxel-fluorouracil chemotherapy, were recruited, and the predictive function of BRCA1 in personalized treatment was analyzed. Fluorouracil was used in both regimens, as the presence of BRCA1 did not confer resistance or sensitivity to fluorouracil.
High expression of BRCA1 mRNA was negatively associated with RR and mOS in patients treated with cisplatin-fluorouracil chemotherapy. Conversely, high BRCA1 expression was also positively associated with clinical outcomes in those who received docetaxel-fluorouracil chemotherapy. As a dual predictive biomarker, the results were consistent with previous findings by the present authors (40, 41) . The findings supported the hypothesis that the use of a combination of HDRA and qPCR is able to effectively distinguish biomarkers in their ability to evaluate response to chemotherapy.
In summary, the present study observed that the level of BRCA1, TS and TOP1 mRNA present make these genes suitable as predictable biomarkers to assess the response of cisplatin, docetaxel, fluorouracil or irinotecan in patients with esophageal cancer. Furthermore, the combination of HDRA and qPCR may be an effective method for screening biomarkers to assess chemosensitivity in personalized chemotherapy for esophageal cancer.
